Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Next Previous
Trial Profile

A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors SymBio Pharmaceuticals

    • Most Recent Events

    • 05 Nov 2019 According to a SymBio Pharmaceuticals media release, based on the favorable clinical results from this study BR therapy has been recommended in the National Comprehensive Cancer Network (NCCN) Guidelines in the UnitedStates since 2012.
    • 10 Feb 2015 According to a SymBio Pharmaceuticals media release, this phase II trial generated positive data. The company will continue to pursue approval for refractory/relapsed intermediate/high-grade non-Hodgkin's lymphoma.
    • 01 Jun 2012 Resutls presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a SymBio Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top